- The PULSAR trial achieved its primary endpoint: a statistically significant reduction in pulmonary vascular resistance - - The trial also achieved statistically significant improvements in the key secondary endpoint of six-minute walk distance (6MWD) and other secondary endpoints, including
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 23, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that John Quisel , J.D., Ph.D, Executive Vice
Data from MEDALIST showed significant clinical benefit of Reblozyl in treating anemia in adults with myelodysplastic syndromes PRINCETON, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 9, 2020-- Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 6, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that senior management will participate at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California . On Monday, January 13, 2020 , Habib Dable , Acceleron’s President and
Fulcrum to receive $10 million upfront payment and be eligible for future milestone payments CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 30, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat
Initial results from phase 2 study evaluating an investigational use of luspatercept-aamt in myelofibrosis-associated anemia showed promising clinical activity – companies plan to initiate pivotal, phase 3 study called INDEPENDENCE in 2020 Longer-term follow-up from pivotal phase 3 studies of
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 9, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Jay T.
PRINCETON, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 6, 2019-- Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that following the late-cycle review meeting on December 4, 2019 , they were notified by the U.S.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 6, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Kemal Malik, MB BS, to its Board
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 4, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that it has been included in the recently released